View PDF of blog article here
The $$$ amounts–one might call them, "fees for services rendered"–reveal the truth about who wields the greatest influence on NAMI policies–and whose interests are being served by NAMI.
Another deadly drug recalled – FDA asks Congress for Power to Dictate Warnings Tue, 1 Mar 2005 Public pressure has intensified as FDA’s failure to protect the public from unsafe – even lethal drugs. That failure included the failure to at least warn physicians and the public about severe adverse…
Glaxo Pricing Under DOJ investigation / GAO Report Says Medicaid Overpays for Drugs Wed, 9 Mar 2005 Reuters reports that GlaxoSmithKline is under investigation by the Department of Justice concerning Medicaid drug pricing. The skyrocketing cost of drugs is depleting Medicaid, the nation’s largest health insturance program paid for by…
In a blistering letter addressed to the Secretary of Health and Human Services, Senator Grassley calls upon Michael Leavitt to give “immediate attention” to the serious issues raised by a Northfield Laboratory, non-consensual artificial blood experiment.
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
The Senate Finance committee is cracking down on drug industry "educational grants" to physicians, medical associations and "patient advocacy" groups.
